esophageal squamous cell carcinoma

Lobaplatin (D-19466) (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin (D-19466) is a third-generation platinum anti-neoplastic agent which shows activity for a variety of tumour types and is a promising antitumour chemotherapeutic agent[1][2]. It is a platinum complex with DNA alkylating activity.

PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).

Isobutyl decanoate (Decanoic acid isobutyl ester) can be used as a biomarker for esophageal squamous cell carcinoma and lung cancer, and can be isolated from wine.

IV-23, a potent inhibitor of cell growth both in vitro and in vivo, effectively reduces colony formation, arrests the cell cycle at the M phase, and induces apoptosis in esophageal squamous cell carcinoma through Noxa-mediated pathways. This compound emerges as a promising anticancer agent with significant potential.

CHI-KAT8i5 is a selective inhibitor of KAT8 with a KD of 19.72 μM. It induces apoptosis (Apoptosis) in a dose-dependent manner. CHI-KAT8i5 can inhibit tumor growth in esophageal squamous cell carcinoma, colon cancer, melanoma, gastric cancer, non-small cell adenocarcinoma, and liver cancer.

ZSH-2208 is a retinoic acid A analogue that inhibits tumour cell proliferation and survival through RARγ-TNFAIP3 and retinoid receptors.

UTKO1 (Compound 2) is a derivative of Moverastin with optical activity, which significantly inhibits tumor cell migration by blocking the interaction between 14-3-3ζ and Tiam1. It is useful for research into cancers such as esophageal cancer and squamous cell carcinoma.

SL-3-19 is a tubulin ligand that exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo. It functions by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor vasculature. SL-3-19 is more potent than SL-1-73 and can be utilized in research involving ESCC and similar tumors.

SL-1-73 is a tubulin ligand. It exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting tubulin assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor vasculature. SL-1-73 is useful for research in ESCC and other tumors.

RSK4-IN-2 (compound 16o) is a potent orally active RSK4 inhibitor with an IC50 of 17 nM. It hinders the growth and invasion of esophageal squamous cell carcinoma (ESCC) cells by inhibiting the phosphorylation of RSK4 downstream targets. Additionally, RSK4-IN-2 impedes tumor growth and metastasis in a mouse model of ESCC, making it valuable for ESCC research.

TFAP2β modulator-1 (compound A6) is a potent TFAP2β modulator that enhances the aggregation of TFAP2β by inducing conformational changes in its intrinsically disordered regions. The compound induces apoptosis and exhibits antitumor activity in esophageal squamous cell carcinoma (ESCC) cells, mouse models, and organoids. TFAP2β modulator-1 is applicable for research related to ESCC.

LD-110 is a potent PROTAC degrader targeting LSD1 with a DC50 of 0.44 μM. It promotes LSD1 degradation via a ubiquitin-proteasome-dependent mechanism and enhances H3K4 dimethylation levels. By inducing apoptosis, LD-110 inhibits the growth and survival of various esophageal squamous cell carcinoma (ESCC) cell lines. It is applicable for research on esophageal squamous cell carcinoma.

PROTACBET Degrader-14 is a potent PROTAC compound designed to target BET (bromodomain and extraterminal domain) proteins. It effectively degrades all family members of BET, including BRD2, BRD3, and BRD4. The compound demonstrates significant efficacy in degrading BET proteins in the U2OS osteosarcoma cell line (BRD4 DC50 = 130 nM) and the KYSE180 esophageal squamous cell carcinoma cell line (DC50 = 40 nM). Its mechanism of degradation relies on the ubiquitin-proteasome system. Furthermore, PROTACBET Degrader-14 reduces the expression levels of BET-regulated gene products such as c-Myc, RUNX2, and KRT14, making it a valuable tool for osteosarcoma research.

Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2). Compound C108 can be used in studies about breast tumors and esophageal squamous cell carcinoma.

Canertinib (CI-1033) is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

Afatinib (BIBW 2992) oxalate is an irreversible, orally active bispecific inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFRwt, 0.4 nM for EGFRL858R, 10 nM for EGFRL858R/T790M, and 14 nM for HER2. Afatinib oxalate can be used to study esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.

(R)-Afatinib ((R)-BIBW 2992), an isomer of Afatinib, is a potent, orally administered, irreversible inhibitor targeting the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFR wt, 0.4 nM for EGFR L858R, 10 nM for EGFR L858R/T790M, and 14 nM for HER2, holding potential for research into esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer [1].

ERK-IN-6 (compound 6g) is a potent anti-proliferative agent against esophageal squamous cell carcinoma (ESCC), inducing apoptosis via the ERK pathway, with potential applications in ESCC research [1].

Xerophilusin B, isolated from Isodon xerophilus as an anticancer agent, demonstrates antiproliferative effects on esophageal squamous cell carcinoma (ESCC) cell lines. It induces G2/M cell cycle arrest and mediates apoptosis [1].

Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.

Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4 nM and 9.9 nM, respectively. Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest.

Paclitaxel liposome is a formulation where paclitaxel is encapsulated within liposomes. Paclitaxel, a natural antineoplastic drug, stabilizes tubulin polymerization. This liposomal form offers reduced acute toxicity, extended paclitaxel half-life, and enhanced accumulation at tumor sites. Paclitaxel liposome is utilized in studies related to breast cancer and locally advanced esophageal squamous cell carcinoma.

Cytochalasin Z2, a metabolite produced by the fungus P. semeniperda, exhibits anticancer properties. It effectively inhibits the proliferation of various cancer cell lines, including OE21 esophageal squamous cell carcinoma, U373 MG glioblastoma, A549 lung cancer, B16/F10 melanoma, and Hs 683 glioma, with IC50 values of 70, 86, 99, 29, and 94 µM, respectively.